Veracyte VCYT 深 滬
等待開盤 09-27 09:30:00 美东时间
33.44
+0.620
+1.89%
華盛通- 最 高33.51
- 今 開32.86
- 成交量 81.68万股
- 最 低 32.59
- 昨 收 32.82
- 總市值 26.31亿
- 52周最高 47.3162
- 市盈率 靜 108.29
- 換手率 1.04%
- 52周最低 22.61
- 委 比 -91.21%
- 總股本 7867.16万
- 歷史最高 86.03
- 量 比 0.65
- 振 幅 2.80%
- 歷史最低 4.21
- 每 手 1
- 風險率 5.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veracyte To Present First Prospective Data Predicting Hormone Therapy Benefit In Recurrent Prostate Cancer At ASTRO 2025
Findings are among nine Decipher-focused abstracts being presented at annual conferenceVeracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a
09-24 21:08
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte advances its VAX-31 infant Phase 2 study to evaluate the optimized dose of the 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in infants. The optimized dose includes most serotypes at 4.4mcg and the balance at 3.3mcg, aiming to elicit stronger immune responses. The study, which now includes the optimized dose arm, will provide topline data by the end of the first half of 2027. VAX-31 i...
09-03 11:30
Veracyte Completes Enrollment Of 2,400 Patients In NIGHTINGALE Trial For Percepta Nasal Swab Lung Cancer Test
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab
08-26 20:36
Veracyte Sees FY2025 Sales $496.000M-$504.000M vs $491.856M Est
2025 Financial OutlookThe company is raising full-year 2025 testing revenue guidance to $477 million to $483 million, or 14% to 15% year-over-year growth, from prior guidance of $470 million to $480 million. Adjusting
08-07 04:29
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
BMNR, VCYT, ZG: Cathie Wood Buys $15M More of Ethereum-Linked Bitmine
Cathie Wood’s ARK InvestETFs(exchange-traded funds) poured millions...
07-30 14:55
Veracyte To Replace Triumph Group In The S&P Smallcap 600 Effective Prior To The Opening Of Trading On Tuesday, July 29
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250724-1478929/1478929_tgi6.pdf
07-25 05:17
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
On Friday, Cathie Wood-led Ark Invest made significant trades, with a particula...
06-21 12:19
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp.
06-07 13:24
Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy
On Wednesday, Cathie Wood's Ark Invest sold 40,035 shares of Palantir Technologies Inc, amidst controversy. They bought shares of Guardant Health Inc and Veracyte Inc.
06-05 09:23
